Abstract
Ferumoxytol is an ultra-small superparamagnetic iron oxide (USPIO) particle that is FDA-approved for parenteral treatment of iron deficiency anemia in adults with chronic kidney disease. Because of the association between gadolinium-based contrast agents and nephrogenic systemic fibrosis in patients with severe chronic kidney disease, we sought to evaluate the diagnostic role of ferumoxytol-enhanced MR venography in children with chronic kidney disease. Twenty children underwent 22 high-resolution ferumoxytol-enhanced MR venography examinations at 3.0 T. High-resolution 3-D contrast-enhanced imaging was performed at a minimum of 3 time points following injection of ferumoxytol at a total dose of 4 mg/kg. Two blinded pediatric radiologists independently scored six named veins on ferumoxytol-enhanced MR venography examinations according to a three-point subjective score, where a score ≥2 was considered diagnostic. Additionally, all relevant venous structures in the included field of view were analyzed for occlusive or non-occlusive thrombosis, compression and presence of collaterals. All patients underwent ferumoxytol-enhanced MR venography successfully and without adverse event. The overall scores of the reviewing radiologists for all venous structures were 2.7-2.9. In all cases, the reviewers were confident basing their diagnoses on the ferumoxytol-enhanced MR venography findings. In 12 of 22 examinations, findings on follow-up imaging or invasive procedures were available to correlate with the findings on ferumoxytol-enhanced MR venography. There was complete concordance between the findings from follow-up imaging and invasive procedures with findings from ferumoxytol-enhanced MR venography. Ferumoxytol holds promise as a powerful alternative to gadolinium-based contrast agents for reliable, high-resolution MR venography in children with chronic kidney disease.
Similar content being viewed by others
References
Pagnan L, Tona G, Belgrano M et al (2005) Direct contrast enhanced MR in the study of central venous accesses in children receiving total parenteral nutrition. Radiol Med 110:241–248
Grobner T (2006) Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108
Anzai Y, Prince MR, Chenevert TL et al (1997) MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging 7:209–214
Neuwelt EA, Hamilton BE, Varallyay CG et al (2009) Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 75:465–474
Spinowitz BS, Kausz AT, Baptista J et al (2008) Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19:1599–1605
FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (2015) U.S. Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm. Accessed 1 May 2015
Bremerich J, Bilecen D, Reimer P (2007) MR angiography with blood pool contrast agents. Eur Radiol 17:3017–3024
Ruangwattanapaisarn N, Hsiao A, Vasanawala SS (2015) Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. Pediatr Radiol 45:831–839
Nguyen KL, Khan SN, Moriarty JM et al (2015) High-field MR imaging in pediatric congenital heart disease: initial results. Pediatr Radiol 45:42–54
Jung JW, Kang HR, Kim MH et al (2012) Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 264:414–422
Prince MR, Zhang H, Zou Z et al (2011) Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 196:W138–W143
Lu M, Cohen MH, Rieves D et al (2010) FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 85:315–319
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None
Additional information
This article was awarded the John Kirkpatrick Young Investigator Award at the Society for Pediatric Radiology 2014 meeting.
Rights and permissions
About this article
Cite this article
Luhar, A., Khan, S., Finn, J.P. et al. Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatr Radiol 46, 1332–1340 (2016). https://doi.org/10.1007/s00247-016-3605-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00247-016-3605-z